Stock VRNA VERONA PHARMA PLC
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Verona Pharma plc

Equities

VRNA

US9250501064

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
15.47 USD +1.05% Intraday chart for Verona Pharma plc -1.59% -22.18%
04-22 European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading MT
04-16 European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT

Evolution of the average Target Price on Verona Pharma plc

Price target over the last 5 years

History of analyst recommendation changes

e75495388836a89.bg4GmRd0Hj3LIl3eq-TAEzvsm5FKe5RpywkvuNgtw8M.Nj1T6CEBZGiMcByZmJKOSlKK7dYlIf5YvmVs3fVniIEGOHzcRkFddbp9FA~1452b921bad394345229730dd8c946e7

Analyst Recommendations on Verona Pharma plc

Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating MT
Wedbush Raises Verona Pharma Price Target to $33 From $30, Maintains Outperform Rating MT
Truist Securities Adjusts Price Target on Verona Pharma to $32 From $28, Maintains Buy Rating MT
Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities MT
BTIG Adjusts Price Target on Verona Pharma to $31 From $26, Maintains Buy Rating MT
European Equities Move Lower Following ECB Rate Hike MT
HC Wainwright Adjusts Verona Pharma's Price Target to $32 From $30, Keeps Buy Rating MT
Wedbush Raises Verona Pharma's Price Target to $30 From $23, Maintains Outperform Rating MT
Truist Securities Adjusts Price Target on Verona Pharma to $28 From $20, Maintains Buy Rating MT
BTIG Boosts Price Target on Verona Pharma to $26 From $17, Reiterates Buy Rating MT
ECB, Bank of England Interest Rate Hikes Weigh Down European Equities MT
Wedbush Lowers Verona Pharma's Price Target to $23 From $27 Due to Increased Share Count, Keeps Outperform Rating MT
Wedbush Analyst Assumes Coverage on Verona Pharma at Outperform With $27 Price Target, Up From $23 MT
HC Wainwright Adjusts Verona Pharma's Price Target to $30 From $25, Reiterates Buy Rating MT
Piper Sandler Initiates Coverage on Verona Pharma With Overweight Rating, $31 Price Target MT
Wedbush Raises Verona Pharma's Price Target to $23 From $18, Maintains Outperform Rating MT
Wedbush Cuts Verona Pharma's Price Target to $18 From $25, Adjusting Ensifentrine Launch Estimates; Outperform Rating Kept MT
Canaccord Genuity Adjusts Price Target on Verona Pharma to $23 From $18, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.47 USD
Average target price
34.29 USD
Spread / Average Target
+121.63%
High Price Target
38 USD
Spread / Highest target
+145.64%
Low Price Target
32 USD
Spread / Lowest Target
+106.85%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Verona Pharma plc

Piper Sandler
Wedbush
Truist Securities
BTIG
HC Wainwright
Canaccord Genuity

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VRNA Stock
  4. Consensus Verona Pharma plc